296 related articles for article (PubMed ID: 32244385)
1. Antiproliferative and Antimigration Activities of Fluoro-Neplanocin A via Inhibition of Histone H3 Methylation in Triple-Negative Breast Cancer.
Byun WS; Kim WK; Yoon JS; Jarhad DB; Jeong LS; Lee SK
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32244385
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
Byun WS; Lee GH; Park HG; Lee SK
Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33379275
[TBL] [Abstract][Full Text] [Related]
3. Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Byun WS; Kim WK; Han HJ; Chung HJ; Jang K; Kim HS; Kim S; Kim D; Bae ES; Park S; Lee J; Park HG; Lee SK
Mol Ther Oncolytics; 2019 Dec; 15():140-152. PubMed ID: 31720371
[TBL] [Abstract][Full Text] [Related]
4. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
Zhang L; Deng L; Chen F; Yao Y; Wu B; Wei L; Mo Q; Song Y
Oncotarget; 2014 Nov; 5(21):10665-77. PubMed ID: 25359765
[TBL] [Abstract][Full Text] [Related]
6. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
7. The Vitamin D Analog, MART-10, Attenuates Triple Negative Breast Cancer Cells Metastatic Potential.
Chiang KC; Yeh TS; Chen SC; Pang JH; Yeh CN; Hsu JT; Chen LW; Kuo SF; Takano M; Kittaka A; Chen TC; Sun CC; Juang HH
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110769
[TBL] [Abstract][Full Text] [Related]
8. UNC0638, a G9a inhibitor, suppresses epithelial‑mesenchymal transition‑mediated cellular migration and invasion in triple negative breast cancer.
Liu XR; Zhou LH; Hu JX; Liu LM; Wan HP; Zhang XQ
Mol Med Rep; 2018 Feb; 17(2):2239-2244. PubMed ID: 29207160
[TBL] [Abstract][Full Text] [Related]
9. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Ju Han H; Sub Byun W; Ho Lee G; Kyung Kim W; Jang K; Yang S; Yang J; Woo Ha M; Hong S; Lee J; Shin J; Bong Oh K; Kook Lee S; Park HG
Bioorg Med Chem; 2021 Apr; 35():116072. PubMed ID: 33636429
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
[TBL] [Abstract][Full Text] [Related]
13. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
[TBL] [Abstract][Full Text] [Related]
14. Pomegranate peel extract inhibits expression of β-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells.
Bagheri M; Fazli M; Saeednia S; Kor A; Ahmadiankia N
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):86-91. PubMed ID: 29974851
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition.
Yar Saglam AS; Kayhan H; Alp E; Onen HI
Mol Biol Rep; 2021 Jan; 48(1):475-489. PubMed ID: 33389483
[TBL] [Abstract][Full Text] [Related]
16. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
17. DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-κB-HIF1α axis.
Neeli PK; Sahoo S; Karnewar S; Singuru G; Pulipaka S; Annamaneni S; Kotamraju S
FEBS J; 2023 Jan; 290(2):502-520. PubMed ID: 36017623
[TBL] [Abstract][Full Text] [Related]
18. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway.
Yang B; Huang J; Xiang T; Yin X; Luo X; Huang J; Luo F; Li H; Li H; Ren G
J Appl Toxicol; 2014 Jan; 34(1):105-12. PubMed ID: 24122885
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
20. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
